The Lancet· Chong-Rui Xu, Yan Zhang, Guinan Lin, Haiyong Wang, Qiming Wang, Dingzhi Huang, Yan Yu, Jin Zhou, Hua Zhong, Lin Wu, Lingxiang Liu, Jianchun Duan, Zhiyi He, Yongzhong Luo, Hongxu Liu, Bi Chen, Xinmin Yu, Feng Xue, Qian Chu, Sanxing Guo, Runxiang Yang, Jia Zhong, Haifeng Liu, Longhua Sun, Xiaorong Dong, Haichuan Su, Peng Zhang, Bin Yang, Sisi He, Yuanyuan Ji, Lixin Wan, Xinghua Han, Jingyu Zhang, Fei Qiu, Lulu Yang, Wei Shi, Yi-Long Wu, HERON-Lung01 Investigators·· 3 hours agoPickScore73
[Articles] Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China
In brief
Interim analysis of the randomised, open-label, phase 3 trial HERON-Lung01 in China showed that ruzaltatug rezetecan significantly prolonged PFS versus chemotherapy in EGFR-mutated advanced NSCLC that progressed after EGFR-TKI therapy. The source states the drug has a manageable safety profile and supports it as a potential treatment option for this population.
Why it matters
HERON-Lung01 interim analysis compared PFS against chemotherapy and reported safety, aiding assessment of benefit and tolerability in the EGFR-TKI-resistant population.
Source: The Lancet · thelancet.com